ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss
On 13 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3b ATTAIN-MAINTAIN trial …
Post
-
-
UK health secretary Wes Streeting resigns
UK health secretary Wes Streeting has resigned, citing a ‘loss of faith’ in the Labour party’s leadership under Prime Minister …
-
Regulatory round-up: A month of key FDA approvals for cancer drugs
It has been a big month for the oncology space, underpinned by several US approvals in haematological and solid tumour …
-
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS
AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form …
-
ECO 2026: gut hormone signals differ in T1D with obesity
At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY …
-
ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss
On 13 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3b ATTAIN-MAINTAIN trial …
-
UK health secretary Wes Streeting resigns
UK health secretary Wes Streeting has resigned, citing a ‘loss of faith’ in the Labour party’s leadership under Prime Minister …
-
Regulatory round-up: A month of key FDA approvals for cancer drugs
It has been a big month for the oncology space, underpinned by several US approvals in haematological and solid tumour …
-
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS
AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form …
-
ECO 2026: gut hormone signals differ in T1D with obesity
At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY …
-
Zydus to acquire Assertio in $166m deal
Zydus Lifesciences (Zydus) is set to acquire all outstanding Assertio common shares in a deal valued at around $166.4m, through …
-
Coya Therapeutics secures FDA fast track status for COYA 302
Coya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for COYA 302, an investigational …
-
Pfizer receives EC approval for Hympavzi to treat haemophilia
Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or …
-
Trends in Renal Research: Nephrology’s Shift to Focus and Precision
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained …
-
ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition
On 12 May 2026, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3a REDEFINE-1 …
